Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
checkpoint inhibitors
Biotech
BMS exits next-gen Yervoy pact, taking $300M in biobucks with it
Bristol Myers Squibb is walking away from CytomX's potential successor to Yervoy and wiping $300 million off the value of the alliance in the process.
Nick Paul Taylor
Mar 12, 2024 7:07am
Novartis axes TIM-3 cancer candidate after phase 3 flop
Jan 31, 2024 6:59am
Glenmark bags subcutaneous checkpoint inhibitor rights
Jan 25, 2024 9:30am
Genome & Co. posts data from phase 2 microbiome cancer trial
Jan 24, 2024 9:39am
Key to clearing precancerous cells could help treat cancer
Jan 12, 2024 6:30am
Scancell enjoys stock bounce on back of cancer vaccine data
Sep 19, 2023 10:55am